Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.
about
Current therapy of myelodysplastic syndromesEffect of erythropoiesis-stimulating agent policy decisions on off-label use in myelodysplastic syndromes.Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studiesPatient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response.Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.Myelodysplastic syndromes: toward a risk-adapted treatment approach.Update on the pharmacotherapy for myelodysplastic syndromes.Resuscitating a dying marrow: the role of hematopoietic growth factors.Darbepoetin alfa for anemia with myelodysplastic syndrome.Assessing Quality of Care for the Myelodysplastic Syndromes.Influence of patient and provider characteristics on quality of care for the myelodysplastic syndromes.Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.ITACA: A new validated international erythropoietic stimulating agent-response score that further refines the predictive power of previous scoring systems.
P2860
Q34013796-499534B6-C752-4E16-B60E-21EBA4C323D4Q34624263-2C174D93-F9CF-439F-AAF6-41D8241E79AAQ34637063-6005466E-9563-4B2B-8A95-E33A824007FCQ35210630-2AD34DE6-403A-4EC4-A60E-198F5C50014CQ35638905-CC95D86A-B746-48C3-9506-8FA56C7371E2Q37248775-7B0DCB3F-A522-4729-9502-18DC957ED774Q38149315-1B85F6FC-BF8D-4ADB-BE12-AE0A48686C70Q38235662-64948EE6-BBD6-4601-930A-1C71A0A7607EQ38259813-B61AB36C-7816-44E9-8B11-30C6D1AB529DQ38314705-77F1116B-E63E-4269-953D-B0294B4A887EQ38937504-470ED586-FA90-4009-9371-9F64EF2CA091Q39970255-EECD7D2A-4A78-4396-A094-86BE4E8257B3Q47629716-82AA2C41-D196-4B0B-A7F5-BFCA42FC65E0Q48181095-2A6B804B-C5C9-48C6-8077-7CF4ADA28F8C
P2860
Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Patterns of erythropoiesis-sti ...... ency with clinical guidelines.
@en
type
label
Patterns of erythropoiesis-sti ...... ency with clinical guidelines.
@en
prefLabel
Patterns of erythropoiesis-sti ...... ency with clinical guidelines.
@en
P2093
P2860
P1433
P1476
Patterns of erythropoiesis-sti ...... ency with clinical guidelines.
@en
P2093
Amer Zeidan
Amy J Davidoff
Franklin Hendrick
Maria R Baer
Sheila R Weiss
Steven D Gore
P2860
P304
P356
10.1016/J.LEUKRES.2013.02.021
P577
2013-03-21T00:00:00Z